Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery

The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin....

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 62; no. 12
Main Authors Padilla, Emma, Oms, Lluis, Espejo, Elena, Gómez, Laura, Pagespetit, Lurdes, Boada, Núria, Bella, Feliu, Pérez, Josefa
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.12.2018
Subjects
Antibiotic Prophylaxis
Rifampin
Rifaximin
Staphylococcal Infections
Staphylococcus
Susceptibility
antibiotic resistance
rifaximin
surgical prophylaxis
rifampin
Staphylococcus
Online AccessGet full text

Cover

Abstract The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. In all cases, the resistant strains were coagulase-negative staphylococci. The resistance completely reverted after three months. This study shows the emergence of transient resistance to rifampin after rifaximin intake.
AbstractList The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. ABSTRACT The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. In all cases, the resistant strains were coagulase-negative staphylococci. The resistance completely reverted after three months. This study shows the emergence of transient resistance to rifampin after rifaximin intake.
The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. In all cases, the resistant strains were coagulase-negative staphylococci. The resistance completely reverted after three months. This study shows the emergence of transient resistance to rifampin after rifaximin intake.
The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. In all cases, the resistant strains were coagulase-negative staphylococci. The resistance completely reverted after three months. This study shows the emergence of transient resistance to rifampin after rifaximin intake.
Author Pagespetit, Lurdes
Padilla, Emma
Oms, Lluis
Pérez, Josefa
Boada, Núria
Gómez, Laura
Bella, Feliu
Espejo, Elena
Author_xml – sequence: 1
  givenname: Emma
  orcidid: 0000-0003-0521-1897
  surname: Padilla
  fullname: Padilla, Emma
  email: epadilla@catlab.cat
  organization: Microbiology Laboratory, CATLAB, Viladecavalls, Spain epadilla@catlab.cat
– sequence: 2
  givenname: Lluis
  surname: Oms
  fullname: Oms, Lluis
  organization: Surgery Service, Hospital de Terrassa (Consorci Sanitari de Terrassa), Terrassa, Spain
– sequence: 3
  givenname: Elena
  orcidid: 0000-0001-9018-7515
  surname: Espejo
  fullname: Espejo, Elena
  organization: Infectious Diseases Unit, Hospital de Terrassa (Consorci Sanitari de Terrassa), Terrassa, Spain
– sequence: 4
  givenname: Laura
  surname: Gómez
  fullname: Gómez, Laura
  organization: Surgery Service, Hospital de Terrassa (Consorci Sanitari de Terrassa), Terrassa, Spain
– sequence: 5
  givenname: Lurdes
  surname: Pagespetit
  fullname: Pagespetit, Lurdes
  organization: Infection Control Team, Infectious Diseases Unit, Hospital de Terrassa (Consorci Sanitari de Terrassa), Terrassa, Spain
– sequence: 6
  givenname: Núria
  surname: Boada
  fullname: Boada, Núria
  organization: Infection Control Team, Infectious Diseases Unit, Hospital de Terrassa (Consorci Sanitari de Terrassa), Terrassa, Spain
– sequence: 7
  givenname: Feliu
  surname: Bella
  fullname: Bella, Feliu
  organization: Infectious Diseases Unit, Hospital de Terrassa (Consorci Sanitari de Terrassa), Terrassa, Spain
– sequence: 8
  givenname: Josefa
  surname: Pérez
  fullname: Pérez, Josefa
  organization: Microbiology Laboratory, CATLAB, Viladecavalls, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30249689$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9PHCEUx4mx0dX25tnM0SYdheHnXJpsNrY1ManR9kxY9qHoDKwwY7r_fZmuGnvwBC_vw_cBnwO0G2IAhI4IPiWkUWfz-eIUE8ppTdQOmhHcqlrwVuyiGcZC1Exhto8Ocr7HpeYt3kP7FDesFaqdoXztnenXPlTXkH0eTLBQlepmMOu7TRdttNZXxg2Qqgn94_vSvQiDeYDKxVTdjOnWW9NVVylOJwqRp4DzDuzgn6BaxC6msi_IxELafEQfnOkyfHpeD9Hvb-e_Fj_qy5_fLxbzy9owxoaai9UKLxmhS-loI5UEwbC0wjWSSywZc4IbphxjGAi3DlOzFFKtOLWcW67oIfq6zV2Pyx5WFsKQTKfXyfcmbXQ0Xv_fCf5O38YnLRouFMYl4OQ5IMXHEfKge58tdJ0JEMesmyKAtITItqBftqhNMecE7nUMwXrypIsn_c-TJtPVPm9xk_tG38cxhfIT77HHb5_xGvwikf4FX0-d-A
CitedBy_id crossref_primary_10_1089_sur_2023_327
crossref_primary_10_1128_AAC_00296_20
crossref_primary_10_1016_j_bioorg_2024_107227
crossref_primary_10_3390_antibiotics12030443
crossref_primary_10_1111_liv_15667
crossref_primary_10_1186_s12879_022_07379_2
Cites_doi 10.1016/j.jinf.2014.04.003
10.1177/1060028017701221
10.1128/AAC.02165-16
10.1016/j.ijantimicag.2009.12.017
10.2165/00003495-199549030-00009
10.1007/s10620-017-4598-7
10.1093/jac/39.2.235
10.1086/499950
10.3748/wjg.v22.i29.6638
10.1371/journal.pone.0186120
10.1016/j.jinf.2010.11.004
ContentType Journal Article
Copyright Copyright © 2018 American Society for Microbiology.
Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology
Copyright_xml – notice: Copyright © 2018 American Society for Microbiology.
– notice: Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology
DBID NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1128/AAC.01353-18
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Rifampin Resistance after Rifaximin Use, Padilla et al
Rifampin Resistance after Rifaximin Use
EISSN 1098-6596
ExternalDocumentID 10_1128_AAC_01353_18
AAC01353-18
30249689
Genre Journal Article
GroupedDBID ---
.55
.GJ
0R~
23M
2WC
39C
3O-
4.4
53G
5GY
5RE
5VS
6J9
ACGFO
ADBBV
AENEX
AFMIJ
AGNAY
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CS3
DIK
E3Z
EBS
EJD
F5P
FRP
GX1
HH5
HYE
HZ~
H~9
J5H
K-O
KQ8
L7B
LSO
MVM
NEJ
NPM
O9-
OK1
P2P
RHF
RHI
RNS
RPM
RSF
TR2
UHB
VH1
W2D
W8F
WH7
WHG
WOQ
X7M
X7N
XOL
Y6R
ZGI
ZXP
~A~
-
0R
55
AAPBV
ABFLS
ADACO
BXI
H13
HZ
ZA5
AAYXX
AGVNZ
CITATION
7X8
5PM
ID FETCH-LOGICAL-a444t-56dd0b413b7f32787e6407c6f27570744f65a48f440e15cf03ab678d53c55c583
IEDL.DBID RPM
ISSN 0066-4804
IngestDate Tue Sep 17 21:23:07 EDT 2024
Wed Jul 17 03:59:05 EDT 2024
Thu Sep 12 17:21:14 EDT 2024
Tue Dec 28 13:59:23 EST 2021
Sun Jul 28 06:55:32 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords antibiotic resistance
rifaximin
surgical prophylaxis
rifampin
Staphylococcus
Language English
License Copyright © 2018 American Society for Microbiology.
All Rights Reserved. https://doi.org/10.1128/ASMCopyrightv2
All Rights Reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a444t-56dd0b413b7f32787e6407c6f27570744f65a48f440e15cf03ab678d53c55c583
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation Padilla E, Oms L, Espejo E, Gómez L, Pagespetit L, Boada N, Bella F, Pérez J. 2018. Rifampin resistance in staphylococci after rifaximin intake for surgical prophylaxis in elective colorectal surgery. Antimicrob Agents Chemother 62:e01353-18. https://doi.org/10.1128/AAC.01353-18.
ORCID 0000-0003-0521-1897
0000-0001-9018-7515
OpenAccessLink https://aac.asm.org/content/aac/62/12/e01353-18.full.pdf
PMID 30249689
PQID 2112191179
PQPubID 23479
PageCount 3
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6256800
proquest_miscellaneous_2112191179
crossref_primary_10_1128_AAC_01353_18
asm2_journals_10_1128_AAC_01353_18
pubmed_primary_30249689
PublicationCentury 2000
PublicationDate 2018-12-01
PublicationDateYYYYMMDD 2018-12-01
PublicationDate_xml – month: 12
  year: 2018
  text: 2018-12-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Antimicrobial agents and chemotherapy
PublicationTitleAbbrev Antimicrob Agents Chemother
PublicationTitleAlternate Antimicrob Agents Chemother
PublicationYear 2018
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References 28622735 - Ann Pharmacother. 2017 Jul;51(7):617-618
24780764 - J Infect. 2014 Sep;69(3):295-7
21073894 - J Infect. 2011 Jan;62(1):34-8
16421799 - Clin Infect Dis. 2006 Feb 15;42(4):541-7
28589238 - Dig Dis Sci. 2017 Sep;62(9):2455-2463
27547007 - World J Gastroenterol. 2016 Aug 7;22(29):6638-51
7774516 - Drugs. 1995 Mar;49(3):467-84
9069545 - J Antimicrob Chemother. 1997 Feb;39(2):235-40
27795384 - Antimicrob Agents Chemother. 2016 Dec 27;61(1)
20185278 - Int J Antimicrob Agents. 2010 Jun;35(6):519-23
28982166 - PLoS One. 2017 Oct 5;12(10):e0186120
Lewis, PO, Khan, I, Patel, P (B9) 2017; 51
B10
Pimentel, M, Cash, BD, Lembo, A, Wolf, RA, Israel, RJ, Schoenfeld, P (B11) 2017; 62
Drancourt, M, Stein, A, Argenson, JN, Roiron, R, Groulier, P, Raoult, D (B12) 1997; 39
Shayto, RH, Abou Mrad, R, Sharara, AI (B2) 2016; 22
Tupin, A, Gualtieri, M, Roquet-Banères, F, Morichaud, Z, Brodolin, K, Leonetti, JP (B4) 2010; 35
Adachi, JA, DuPont, HL (B3) 2006; 42
DuPont, HL, Wolf, RA, Israel, RJ, Pimentel, M (B6) 2017; 61
Gillis, JC, Brogden, RN (B1) 1995; 49
Valentin, T, Leitner, E, Rohn, A, Zollner-Schwetz, I, Hoenigl, M, Salzer, HJ, Krause, R (B5) 2011; 62
Valentin, T, Hoenigl, M, Wagner, J, Krause, R, Zollner-Schwetz, I (B8) 2014; 69
Chang, JY, Kim, SE, Kim, TH, Woo, SY, Ryu, MS, Joo, YH, Lee, KE, Lee, J, Lee, KH, Moon, CM, Jung, HK, Shim, KN, Jung, SA (B7) 2017; 12
e_1_3_2_9_2
e_1_3_2_8_2
e_1_3_2_7_2
e_1_3_2_6_2
e_1_3_2_10_2
e_1_3_2_5_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_2_2
References_xml – volume: 69
  start-page: 295
  year: 2014
  end-page: 297
  ident: B8
  article-title: Bacteraemia with rifampin-resistant Staphylococcus aureus and the potential role of cross-resistance between rifampin and rifaximin
  publication-title: J Infect
  doi: 10.1016/j.jinf.2014.04.003
  contributor:
    fullname: Zollner-Schwetz, I
– volume: 51
  start-page: 617
  year: 2017
  end-page: 618
  ident: B9
  article-title: Rifampin-resistant Staphylococcus aureus bacteremia in a patient on chronic rifaximin
  publication-title: Ann Pharmacother
  doi: 10.1177/1060028017701221
  contributor:
    fullname: Patel, P
– volume: 61
  year: 2017
  ident: B6
  article-title: Antimicrobial susceptibility of Staphylococcus isolated from skin of patients with diarrhea-predominant irritable bowel syndrome treated with repeat courses of rifaximin
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02165-16
  contributor:
    fullname: Pimentel, M
– volume: 35
  start-page: 519
  year: 2010
  end-page: 523
  ident: B4
  article-title: Resistance to rifampin: at the crossroads between ecological, genomic and medical concerns
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2009.12.017
  contributor:
    fullname: Leonetti, JP
– volume: 49
  start-page: 467
  year: 1995
  end-page: 484
  ident: B1
  article-title: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria
  publication-title: Drugs
  doi: 10.2165/00003495-199549030-00009
  contributor:
    fullname: Brogden, RN
– volume: 62
  start-page: 2455
  year: 2017
  end-page: 2463
  ident: B11
  article-title: Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity
  publication-title: Dig Dis Sci
  doi: 10.1007/s10620-017-4598-7
  contributor:
    fullname: Schoenfeld, P
– volume: 39
  start-page: 235
  year: 1997
  end-page: 240
  ident: B12
  article-title: Oral treatment of Staphylococcus spp. infected orthopedic implants with fusidic acid or ofloxacin in combination with rifampicin
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/39.2.235
  contributor:
    fullname: Raoult, D
– volume: 42
  start-page: 541
  year: 2006
  end-page: 547
  ident: B3
  article-title: Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders
  publication-title: Clin Infect Dis
  doi: 10.1086/499950
  contributor:
    fullname: DuPont, HL
– volume: 22
  start-page: 6638
  year: 2016
  end-page: 6651
  ident: B2
  article-title: Use of rifaximin in gastrointestinal and liver diseases
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v22.i29.6638
  contributor:
    fullname: Sharara, AI
– volume: 12
  year: 2017
  ident: B7
  article-title: Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0186120
  contributor:
    fullname: Jung, SA
– ident: B10
  article-title: European Committee on Antimicrobial Susceptibility Testing . 2016 . Breakpoint tables for interpretation of MICs and zone diameters, version 6.0 . European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf .
– volume: 62
  start-page: 34
  year: 2011
  end-page: 38
  ident: B5
  article-title: Rifaximin intake leads to emergence of rifampin-resistant staphylococci
  publication-title: J Infect
  doi: 10.1016/j.jinf.2010.11.004
  contributor:
    fullname: Krause, R
– ident: e_1_3_2_12_2
  doi: 10.1007/s10620-017-4598-7
– ident: e_1_3_2_2_2
  doi: 10.2165/00003495-199549030-00009
– ident: e_1_3_2_3_2
  doi: 10.3748/wjg.v22.i29.6638
– ident: e_1_3_2_4_2
  doi: 10.1086/499950
– ident: e_1_3_2_7_2
  doi: 10.1128/AAC.02165-16
– ident: e_1_3_2_5_2
  doi: 10.1016/j.ijantimicag.2009.12.017
– ident: e_1_3_2_6_2
  doi: 10.1016/j.jinf.2010.11.004
– ident: e_1_3_2_9_2
  doi: 10.1016/j.jinf.2014.04.003
– ident: e_1_3_2_8_2
  doi: 10.1371/journal.pone.0186120
– ident: e_1_3_2_13_2
  doi: 10.1093/jac/39.2.235
– ident: e_1_3_2_10_2
  doi: 10.1177/1060028017701221
SSID ssj0006590
Score 2.3608725
Snippet The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis....
SourceID pubmedcentral
proquest
crossref
asm2
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
SubjectTerms Antibiotic Prophylaxis
Rifampin
Rifaximin
Staphylococcal Infections
Staphylococcus
Susceptibility
Title Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery
URI https://www.ncbi.nlm.nih.gov/pubmed/30249689
https://journals.asm.org/doi/10.1128/AAC.01353-18
https://search.proquest.com/docview/2112191179
https://pubmed.ncbi.nlm.nih.gov/PMC6256800
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB5iQ0svpXFf7iNsS5tTZEv70K6PxiSkLS5uHpCbWK1WRDSWjWVD_e87q5WSOKGXHoVmJcE3O_ONdh4AX4zQGZOuup1KHfCU8gBDMBkYmqswZ8aakasdnv6MTy_59ytxtQeirYWpk_ZNWgzKm_mgLK7r3Mrl3AzbPLHhbDpBzh4j0Rl2oCMZa0P0xvzGwv9YQV8acBXyNtudquF4PBmEbtBDELk5fcy1y4vdgPeuruZ01zM9opsPsybvuaGTF_C84Y9k7L9zH_Zs2YMnfqLktgdPp81ZeQ8OZ74r9faIXNwVWVVH5JDM7vpVb19CdVbker4sSnJmK0cnUQ8IXiEPRQzQ2S2MKUg9TJw40T9uEBj5Vq71b0uQ85Lzzaq2n2S2WrgVKFG5BxzfeGtKJvgmZ1lR5NyXYb-Cy5Pji8lp0MxiCDTnfB2IOMvCFD1eKnNGcZdbdwJo4pxKIZGG8DwWmquc89BGwuQh0yn6wUwwI4QRir2Gbrko7VsgUapHkhkkIlnOqYm0FqllYuSasVk6yvrw2cGRNJupSuo4haoE4Utq-JJI9eFrC1ay9H05_iH3qUUywY3jTkN0aRebKsHIF62164jXhzce2dsntZrRB7mD-a2Aa8q9ewd1tW7O3ejmu_9e-R6eISlTPmXmA3TXq439iMRnnR5A58cvdVCr-1_FcgHj
link.rule.ids 230,315,733,786,790,891,27957,27958,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NIj5e-CgDyqdBsKclTRw7SR-ralMH61RtHdpbZDuOiLamVZNKlL-ec5xsdIgHeIx8cRTl57uf47vfAXxSXKRBZKrbaSQcJilzcAsWOYpmsZcFSquBqR2enITjc_blgl_sAG9rYeqkfSVzt7iau0X-vc6tXM5Vv80T608nI-TsIRKd_h24i-uVRu0mvXHAIbe_VjCaOiz2WJvvTuP-cDhyPdPqwfFNp77ACOaFpsV7R5Rzuh2b_iCct_MmfwtEh4_hW_sKNv_k0l1X0lU_b6k7_vM7PoFHDTUlQzv8FHZ00YV7tlnlpgv3J80xfBf2plbwerNPZjf1W-U-2SPTGynszTMoT_NMzJd5QU51aZgqQozgFVJc_LwYRxdK5aTuU06M6Q_TY4wcFZW41ATpNDlbr2rXTKarhbkDLUozwcGVddRkhE8yThtNzmyF9y6cHx7MRmOnafPgCMZY5fAwTT2JwVRGWUDRgWhzuKjCjEY8QobDspALFmeMedrnKvMCITHEpjxQnCseB8-hUywK_RKIL8UgChRynDRjVPlCcKkDPjA6b5oO0h58NN85adZpmdRbIBoniIukxkXixz343KIgWVrJj7_YfWghkuCaNActotCLdZngphoDgRHb68ELC5nrmVrI9SDaAtO1gdH73h5BiNS63w0kXv33ne_hwXg2OU6Oj06-voaHyP1im5nzBjrVaq3fIr-q5Lt6Nf0CnUUi4Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD6CIiZeBpTLytUg2NNyc-xcHquyagM6VbtI014ix7FFtDWtmlSi_HqOc9nWIV72GOXYkeXP53yOj78D8EVykfmhud1OQ2GxlDILt2ChJamOXO1LJWNzd3hyFBycse_n_PxWqa86aV-muV1czewi_1XnVi5m0unyxJzpZIScPUCi4ywy7TyER7hmadxt1FsnHPDm9wpGVItFLuty3mnkDIcj2zXlHizPVOvzjWheYMq890Q5o5vx6R_SeTd38lYwGj-Fi24YTQ7Kpb2qUlv-uaPweK9xPoPtlqKSYWPyHB6oog-Pm6KV6z5sTdrj-D7sThvh6_UeOb25x1XukV0yvZHEXr-A8jjXYrbIC3KsSsNYEWoEn5Dq4jRjPJ1LmZO6Xjkxpr9NrTFyWFTiUhGk1eRktaxdNJku56YFWpSmg_2rxmGTEX7JOG80OWluer-Es_H-6ejAass9WIIxVlk8yDI3xaCahtqn6EiUOWSUgaYhD5HpMB1wwSLNmKs8LrXrixRDbcZ9ybnkkf8KesW8UDtAvFTEoS-R62SaUekJwVPl89jovSkaZwP4bOY6addrmdRbIRoliI2kxkbiRQP42iEhWTTSH_-x-9TBJMG1aQ5cRKHmqzLBzTUGBCO6N4DXDWyue-pgN4BwA1DXBkb3e_MNwqTW_25h8ebeLT_C1vTbOPl5ePTjLTxBChg1CTrvoFctV-o90qwq_VAvqL_ACSVh
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rifampin+Resistance+in+Staphylococci+after+Rifaximin+Intake+for+Surgical+Prophylaxis+in+Elective+Colorectal+Surgery&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Padilla%2C+Emma&rft.au=Oms%2C+Lluis&rft.au=Espejo%2C+Elena&rft.au=G%C3%B3mez%2C+Laura&rft.date=2018-12-01&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=62&rft.issue=12&rft_id=info:doi/10.1128%2FAAC.01353-18&rft_id=info%3Apmid%2F30249689&rft.externalDBID=PMC6256800
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon